This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (32)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Review  • Adverse Effects  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

David A. Flockhart, MD, PhD; Jose E. Tanus-Santos, MD, PhD

Arch Intern Med. 2002;162:405-412.

Many of the estimated 50 million Americans with high blood pressure receive medications for hypertension and for other conditions, placing them at risk for adverse drug interactions. The risk for hypertension and for adverse drug reactions is highest in the elderly, who have the greatest need for pharmacologic therapy. The most important class of drug interactions involves the cytochrome P450 microsomal enzyme system, which handles a variety of xenobiotic substances. A potential for interactions with these enzymes exists with calcium channel blockers, -adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers but not with diuretic antihypertensives, which are renally eliminated and more vulnerable to drug interactions that occur in the kidney. This article reviews the cytochrome P450 enzyme system, identifies drugs and foods that have been implicated in metabolic interactions with antihypertensive agents, and suggests measures for reducing the risk of adverse events when drugs are coadministered.

From the Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis. Dr Flockhart is now with the Department of Medicine, Indiana University School of Medicine, Wishard Hospital, Indianapolis.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTER

Ethnic, Racial, and Sex-Specific Factors Are Important in Cardiovascular Pharmacotherapeutics
Vincent J. Caracciolo, Benjamin M. Shaefer, Pamela Charney, David A. Flockhart, and Jose Eduardo Dos Santos
Arch Intern Med. 2002;162(21):2494-2495.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Potential drug-drug interactions with antiepileptic drugs in Medicaid recipients
Dickson et al.
Am J Health Syst Pharm 2008;65:1720-1726.
ABSTRACT | FULL TEXT  

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel
Suh et al.
CMAJ 2006;174:1715-1722.
ABSTRACT | FULL TEXT  

Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly
Wasil and Lichtman
The Oncologist 2005;10:602-612.
ABSTRACT | FULL TEXT  

Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting
Gorchakova et al.
Eur Heart J 2004;25:1898-1902.
ABSTRACT | FULL TEXT  

Ethnic, Racial, and Sex-Specific Factors Are Important in Cardiovascular Pharmacotherapeutics
Caracciolo et al.
Arch Intern Med 2002;162:2494-2495.
FULL TEXT  

Common Drug Pathways and Interactions
Kroner
Diabetes Spectr. 2002;15:249-255.
ABSTRACT | FULL TEXT